Latest Innovation News

Adherium Limited has exceeded its 2025 shipment goals by delivering over 4,600 Hailie® Smartinhaler® devices, including more than 2,000 to Remote Patient Monitoring patients, signaling robust operational momentum.

EVT Limited has acquired the premium QT Auckland hotel for NZ$87.5 million, reinforcing its strategic presence in key city markets while divesting non-core assets to focus on high-performing properties.

InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.

Zoono Group Limited has responded to ASX queries confirming ongoing collaboration with OSY Group Limited, acknowledging delays in meeting sales targets but highlighting steady contract progress and future order potential.

Renascor Resources has completed major equipment installation and begun commissioning at its Australian Government co-funded Purified Spherical Graphite demonstration facility, marking a pivotal step in its sustainable battery anode materials strategy.

Latrobe Magnesium Limited has received a $6.29 million R&D tax rebate from the ATO, using the funds to reduce debt and progress its magnesium production plants in Australia and Malaysia.

Carnegie Clean Energy’s Spanish subsidiary has sold its 2025 Basque R&D tax deductions for €773,163, securing immediate funding to advance its ocean wave energy technology under the ACHIEVE Programme.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Elevate Uranium Ltd has expanded its global uranium resource to 169 million pounds of U3O8 through the acquisition of the Napperby Uranium Project and complementary assets from Core Lithium Ltd. This move consolidates its Central Australian portfolio and leverages its proprietary U-pgrade™ beneficiation technology.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Adisyn Ltd has completed a strategic review, deciding to boost investment in its graphene-based semiconductor arm while exploring options to unlock value from its managed IT services business.

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.